Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Little Gorilla who wrote (20097)	3/25/1999 11:30:00 AM
From: Mkilloran	Read Replies (1) \| Respond to of 23519

LG...Vivus sells Muse to Astra and Janssen for about $7 a pellet, or $42 a script (6 * 7 = 42). In China they have a royalty sharing agreement with Janssen.

To: Little Gorilla who wrote (20097)	3/25/1999 11:34:00 AM
From: VLAD	Respond to of 23519

The current arrangement between Vivus and Astra and Janssen is a per unit cost for MUSE. Vivus will not give exact numbers but has said that the analysts estimate the per unit costs between $6.00 and $7.00/unit for Astra/Janssen. Product cost bases is another point of debate and certainly at this point will vary with the unit volume production (ie the more Vivus makes a given quarter the cheaper the costs). My current "guess" is that with the new production facility but lower production volume Vivus' costs are about $4.50 per unit but I really don't know. Perhaps someone can discuss current per unit production costs with Vivus and let us all know.